Most clinical trials indicate that semaglutide does not cause significant liver damage in most patients
Long-acting formulations (e.g., liraglutide, dulaglutide and semaglutide) predominantly enhance insulin secretion and suppress glucagon release, leading to sustained glycaemia [37, 38] (Fig
An exploratory signal suggested a potential lower risk of heart failure hospitalization with semaglutide compared to dapagliflozin
It is established cardiac pharmacology, documented in the NEJM paper: "Glucagon and GLP-1 can exert positive chronotropic and inotropic effects on the heart." GLP-1 also contributes: GLP-1 receptor activation by itself produces a modest chronotropic effect this is why semaglutide and tirzepatide raise heart rate by 14 bpm
The liver is the main organ for vitamin B12 storage
As the use of medications to support weight loss continues to rise, we see an opportunity to serve those consumers